Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from ...
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...
Truist analyst Richard Newitter raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Hold rating on the shares as ...
On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback